Serial No.:

| List of Patents and Publications for Applicant's                |                               |   |  | ARCD:389US 10/751,606   |   |  |  |
|---|-------------------------------|---|--|---|---|--|--|
|   |                               |   |  | Applicant: Mark J. RATAIN et al.  |   |  |  |
|   |                               |   |  |   |   |  |  |
| W 11 4 75   |                               |   |  | Filing Date:  | Group:  |  |  |
| (Use several sheets if necessary)                               |                               |   | January 5, 2004  | 1634  |   |  |  |
| U.S. Patent Documents   |                               |   | Foreign Patent Documents   |   | Other Art   |  |  |
| See Page 1  |                               |   | See Page 1   |   | See Page 1  |  |  |
|   |                               |   |  |   |   |  |  |
| U.S. Patent Documents   |                               |   |  |   |   |  |  |
| Exam.<br>Init.  | Ref.<br>Des.                  | Document<br>Number  | Date   | Name  | Class   | Sub<br>Class   | Filing Date of App.  |
|   |                               |   |  |   |   |  |  |
| Foreign Patent Documents  |                               |   |  |   |   |  |  |
| Exam.<br>Init.  | Ref.<br>Des.                  | Document<br>Number  | Date   | Country   |   | Language   |  |
|   |                               |   |  |   |   |  |  |
| Other Art (Including Author, Title, Date Pertinent Pages, Etc.) |                               |   |  |   |   |  |  |
|   |                               | Citation  |  |   |   |  |  |
| Exam.<br>Init.  | Ref.<br>Des.                  |   |  | Citation  |   |  | •  |
|   |                               | "Prosecution history  | for 90/007,60  | Citation  1," Reexamination of Uni  | ted States I  | Patent Numb  | per 6,395,481  |
|   | Des.                          | Cote et al., "UGT1.   | A1 polymorphi  |   |   |  |  |
|   | Des.<br>C222                  | Cote et al., "UGT1.<br>irinotecan," Clin. C   | A1 polymorphi<br>ancer Res., 130<br>dividual genoty<br>ne COLOGEN  | 1," Reexamination of Uni<br>ism can predict hematolo<br>(11):3269-3275, 2007.<br>rping to optimize chemot<br>trial," J. Clin. Oncology,   | gic toxicity  | in patients  | treated with   |
|   | C222<br>C223                  | Cote et al., "UGT1. irinotecan," Clin. C Falandry et al., "Inc cancer (MCRC): Ti Proceedings Part I, Innocenti et al., "A   | Al polymorphi<br>ancer Res., 13(<br>dividual genoty<br>ee COLOGEN<br>25(18S):2510,<br>genotype-direc   | 1," Reexamination of Uni<br>ism can predict hematolo<br>(11):3269-3275, 2007.<br>rping to optimize chemot<br>trial," J. Clin. Oncology,   | gic toxicity herapy in 1 2007 ASC   | netastatic co<br>CO Annual M   | treated with   |
|   | C222<br>C223<br>C224          | Cote et al., "UGTL<br>irinotecan," Clin. C<br>Falandry et al., "Inc<br>cancer (MCRC): Tl<br>Proceedings Part I,<br>Innocenti et al., "A<br>J. Clin. Oncology,"  | A1 polymorphi<br>dancer Res., 130<br>dividual genoty<br>ne COLOGEN<br>25(18S):2510,<br>genotype-direct<br>2007 ASCO Ar<br>midation of TA   | 1," Reexamination of Unition can predict hematolo (11):3269-3275, 2007.  ping to optimize chemot trial," J. Clin. Oncology, 2007.   | herapy in 1<br>2007 ASC<br>otecan in a<br>gs Part I, 2  | netastatic co<br>CO Annual M<br>dvanced can<br>5(18S):2502   | treated with  blorectal Aeeting  acer patients," 2, 2007.                          |
|   | C222 C223 C224 C225           | Cote et al., "UGTLirinotecan," Clin. C Falandry et al., "Inc cancer (MCRC): TI Proceedings Part I, Innocenti et al., "A J. Clin. Oncology, Iyer et al., "Glucuro Oncol., 17:187a, Nc Owens and Ritter,"   | Al polymorphi<br>ancer Res., 13(<br>dividual genoty<br>the COLOGEN<br>25(18S):2510,<br>genotype-direc<br>2007 ASCO Ar<br>midation of TA<br>5. 722, 1998.<br>The novel bilinitiple nonhemoi   | 1," Reexamination of Uni<br>sm can predict hematolo<br>(11):3269-3275, 2007.<br>ping to optimize chemot<br>trial," J. Clin. Oncology,<br>2007.<br>tetad phase I study of irin<br>nual Meeting Procedin<br>S-103: A Novel Anticanc<br>ubin/phenol UDP-glucurc<br>tytic familial hyperbilirub       | herapy in 1<br>2007 ASC<br>otecan in a<br>gs Part I, 2<br>er Agent,"  | v in patients metastatic cc O Annual M dvanced can 5(18S):2502 Proc. Am. S ferase UGT  | treated with blorectal Meeting cer patients," 2, 2007.                             |
|   | C222 C223 C224 C225 C226      | Cote et al., "UGTLirinoteean," Clin. C Falandry et al., "Incancer (MCRC): TI Proceedings Part I, Innocenti et al., "A. Clin. Oncology,' Iyer et al., "Glucuro Oncol., 17:187a, No Owens and Ritter," implications for mu Pharamcogenetics,  | A1 polymorphi<br>ancer Res., 13d<br>dividual genoty<br>the COLOGEN<br>25(188):2510,<br>genotype-direct<br>2007 ASCO Ar<br>midation of TA<br>5. 722, 1998.<br>The novel bilin<br>tiple nonhemoi<br>2:93-108, 1992<br>the Role of Gluck                      | I," Reexamination of Uni<br>sm can predict hematolo<br>(11):3269-3275, 2007.<br>ping to optimize chemot<br>trial," J. Clin. Oncology,<br>2007.<br>ted phase I study of irin<br>nunal Meeting Proceeding<br>S-103: A Novel Anticanc<br>ubin/phenol UDP-glucure<br>tytic familial hyperbilirub.<br> | gic toxicity herapy in 1 2007 ASC  otecan in a gs Part I, 2 er Agent," onosyltrans inemia phe                           | vin patients metastatic oc CO Annual M dvanced can 5(18S):2502 Proc. Am. S ferase UGT enotypes,"   | treated with  olorectal Aceting  cer patients," 2, 2007.  oc. Clin.  I gene locus: |
|   | C222 C223 C224 C225 C226 C227 | Cote et al., "UGTLi rinotecan," Clin. C Falandry et al., "Incancer (MCRC): TI Proceedings Part I, Innocenti et al., "A. Clin. Oncology, 2 lyer et al., "Glucuro Oncol., 17:187a, Nc Owens and Ritter, "implications for mu Pharamcogenetics, Takahashi et al., "Titro," Jpn. J. Canc. Utsugi et al., "Antit | A1 polymorphi<br>ancer Res., 13(<br>dividual genotyne<br>ne COLOGEN<br>25(18S):2510,<br>genotype-direc<br>2007 ASCO Ar<br>midation of TA.<br>0. 722, 1998.<br>The novel bilir<br>litiple nonhemoi<br>2:93-108, 1992<br>the Role of Glue<br>er Res., 88:121 | I," Reexamination of Uni<br>sm can predict hematolo<br>(11):3269-3275, 2007.<br>ping to optimize chemot<br>trial," J. Clin. Oncology,<br>2007.<br>ted phase I study of irin<br>nunal Meeting Proceeding<br>S-103: A Novel Anticanc<br>ubin/phenol UDP-glucure<br>tytic familial hyperbilirub.<br> | gic toxicity therapy in 1 2007 ASC  otecan in a gs Part I, 2 er Agent," onosyltrans inemia phe  O-hydroxyc rivative, TA | vin patients vin p | treated with olorectal Aceting cer patients," 2, 2007. 'co. Clin.  I gene locus:   |

Atty. Docket No.:

25797494.1

Form PTO-1449 (modified)

EXAMINER: /Sarae Bausch/ DATE CONSIDERED: 08/12/2008

EXAMINER: NITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS NO COMPONEMANCE WITH MFEF609. DAWN LINE THROUGH

CITATION IS NOT IN CONPROMANCE AND NOT CONSIDERED. INCLUDE CORY OF THIS FORM WITH NEXT COMMUNICATION TO A OFFICIANT.